You are currently viewing SARS-CoV-2 lateral flow antigen tests: evaluation of VUI-202012/01

SARS-CoV-2 lateral flow antigen tests: evaluation of VUI-202012/01


Working with academic collaborators at the University of Oxford, PHE Porton Down has been evaluating the performance of lateral flow devices (LFDs) since mid-August 2020. Over 60 have been considered to date, approximately 30% of which have progressed to extended evaluation on clinical samples at Phase 3.



Source link